Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Tsuyoshi Muta, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Yoshimasa Suetsugu, MD, Masaaki Noda, MD, Tasuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Tatsuji Mino, Ryota Imanaka, MD, Kohei Kyo, MD, Yuta Katayama, MD PhD, Shinya Katsutani, MD PhD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2018-99-116016

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Tatsuji Mino, Yuta Katayama, MD PhD, Tatsuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Takeshi Okatani, MD, Ryota Imanaka, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Shinya Katsutani, MD PhD, Tsuyoshi Muta, MD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2018-99-113461

Published: 2018

Journal Articles

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Yoshitaka Miyakawa, MD, PhD, Shinya Katsutani, MD, PhD, Takahiro Yano, MD, PhD, Shosaku Nomura, MD, PhD, Kaichi Nishiwaki, MD, Yoshiaki Tomiyama, MD, PhD, Masaaki Higashihara, MD, PhD, Yukari Shirasugi, MD, PhD, Masakatsu Nishikawa, MD, PhD, Katsutoshi Ozaki, MD, PhD, Kayoko Kikuchi, Takayuki Abe, PhD, Yuji Sato, MD, PhD, Yuzuru Kanakura, Kingo Fujimura, MD, PhD, Yasuo Ikeda, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 3554.

https://doi.org/10.1182/blood.V122.21.3554.3554

Published: 2013

Journal Articles

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Yoshiaki Tomiyama, MD, Yoshitaka Miyakawa, MD, PhD, Shinichiro Okamoto, MD, PhD, Shinya Katsutani, MD, Akiro Kimura, MD, Yasushi Okoshi, MD, PhD, Haruhiko Ninomiya, MD, PhD, Hiroshi Kosugi, MD, PhD, Shosaku Nomura, MD, Katsutoshi Ozaki, MD, Yasuo Ikeda, MD, Nobuyuki Koh, Koichi Katsura, MD, PhD, Yuzuru Kanakura, MD, PhD

Blood (2009) 114 (22): 1324.

https://doi.org/10.1182/blood.V114.22.1324.1324

Published: 2009

Journal Articles

Monoclonal antibody IAC-1 is specific for activated α 2 β 1 and binds to amino acids 199 to 201 of the integrin α 2 I-domain

Anne Schoolmeester, Karen Vanhoorelbeke, Shinya Katsutani, Hilde Depraetere, Hendrik B. Feys, Johan M. W. Heemskerk, Marc F. Hoylaerts, Hans Deckmyn

Blood (2004) 104 (2): 390–396.

https://doi.org/10.1182/blood-2003-12-4224

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Rituximab As Second-Line Treatment For Chronic Immune Thrombocytopenia: Investigator-Initiated Clinical Trial In Japan

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Monoclonal antibody IAC-1 is specific for activated α 2 β 1 and binds to amino acids 199 to 201 of the integrin α 2 I-domain

Email alerts

ASH Publications

American Society of Hematology